Grace Therapeutics announces presentation of Phase 3 STRIVE-ON safety trial

Grace Therapeutics (GRCE) announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH were presented at the 2025 Neurocritical Care Society annual meeting, held in Montreal, Quebec, Canada September 18-21, 2025. In an oral presentation titled Safety and Tolerability of GTx-104Compared with Oral Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage: a Prospective, Randomized Trial, Dr. H. Alex Choi highlighted the trial results demonstrating the safety and tolerability of GTx-104 in the treatment of aSAH. The STRIVE-ON safety trial was a prospective, randomized open-label trial of GTx-104 compared with oral nimodipine in patients hospitalized with aSAH. 50 patients were administered GTx-104 and 52 patients received oral nimodipine. The primary endpoint was the number of patients with at least one episode of clinically significant hypotension reasonably considered to be caused by the drug, and additional secondary endpoints included safety, clinical, and pharmacoeconomic outcomes.